A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: The PENTA-4 trial

AIDS

Volumn 12, Issue 14, 1998, Pages

  Gibb, D M ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV 1 infection; Lamivudine; Paediatrics; Randomized placebo controlled clinical trial

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; ZALCITABINE; ZIDOVUDINE;

EID: 7344247127     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Englund JA, Baker CJ, Raskino C, et al.: Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med 1997, 336:1704-1712.
2. ACTG 300 Team: A Randomized Comparative Study of Combined Zidovudine (ZDV)-Lamivudine (3TC) versus the Better of ddl Monotherapy versus Zidovudine plus ddl in Symptomatic HIV-1-Infected Children, 1997. ACTG 300 Executive Summary. Social and Scientific Systems Inc., PACTG Operations Center, Rockville, Maryland.
3. 3 a randomized, double-blind multicenter, controlled trial. Ann Intern Med 1996, 125:161-172.
4. Eron JJ, Benoit SL, Jemsek J: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimetre. N Engl J Med 1995, 333:1662-1669.
5. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine (3TC)/zidovudine (ZDV) in antiretroviral naive HIV-1 infected patients: a comparison with zidovudine monotherapy. JAMA 1996, 276:118-125.
6. Staszewski S, Miller V, Rehmet S, et al.: Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 1996, 10:171-177.
7. Lewis LL, Venzon D, Church J, et al.: Lamivudine in children with human immunodeficiency virus infection: a Phase I/II study. J Infect Dis 1996, 174:16-25.
8. Centers for Disease Control and Prevention: 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994, 43:1-10.
9. Centers for Disease Control and Prevention: Revised guidelines for prophylaxis, against pneumonia Pneumocystis carinii for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995, 44:1-11.
10. Wade AM, Ades AE: Age related reference ranges: significance test for models and confidence intervals for centiles. Stat Med 1994, 13:2359-2367.
11. Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA: Cross-sectional stature and weight reference curves for the UK 1990. Arch Dis Child 1995, 73:17-24.
12. Horneff G, Adams O, Wahn V: Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children. AIDS 1998, 12:489-494.
13. McKinney RE, Maha MA, Connor EM, et al.: A multicentre trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med 1991, 324:1018-1025.
14. CAESAR Coordinating Committee: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. Lancet 1997, 349:1413-1421.
15. McKinney RE: Response of antiretroviral therapy naive children <3 years old to monotherapy ddl or combination ZDV/3TC: a posthoc analysis of data from PACTG protocol 300. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 122].
16. Blanche S, Newell ML, Mayaux MJ, et al.: Morbidity and mortality in European children vertically infected by HIV-1. J Acquit Immune Defic Syndr Hum Retrovirol 1997, 14:442-450.
17. Paediatric European Network for Treatment of AIDS: HIV-1 viral load and CD4 count in untreated children with vertically acquired symptomatic or mild disease. AIDS 1998, 12:F1-F8.
18. Centre for Disease Control and Prevention: Guidelines for use of antiretroviral agents in pediatric HIV infection. MMWR 1998, 47:1-43.